Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-03-21 , DOI: 10.1080/14737167.2024.2333334
Shuo Kang ₁ , Jintuo Yin ₂

Affiliation

The current analysis aimed to evaluate the economic benefit of toripalimab plus axitinib for previously untreated RCC patients from the Chinese healthcare system perspective.The partitioned surviva...

更新日期：2024-03-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南